174666-16-1

Basic information

• Product Name: 4-(2-tert-butoxycarbonylaminoethoxy)benzoic acid methyl ester
• Synonyms: 4-(2-tert-butoxycarbonylaminoethoxy)benzoic acid methyl ester
• CAS NO: 174666-16-1
• Molecular Weight: 295.335
• Mol File: 174666-16-1.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 4-(2-tert-butoxycarbonylaminoethoxy)benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-tert-butoxycarbonylaminoethoxy)benzoic acid methyl ester(174666-16-1)
• EPA Substance Registry System: 4-(2-tert-butoxycarbonylaminoethoxy)benzoic acid methyl ester(174666-16-1)

Safety Data

• Hazardous Substances Data: 174666-16-1(Hazardous Substances Data)

Upstream product

• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 

Downstream Products

• 56850-93-2 methyl 4-(2-Aminoethyloxy)benzoate 
• 783355-60-2 abexinostat 
• 210113-85-2 4-(2-Amino-ethoxy)-benzoic acid methyl ester hydrochloride salt 
• 298692-93-0 3-{4-[2-(N-BOC-amino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid tert-butyl ester 
• 228851-06-7 (S)-3-[4-(2-Amino-ethoxy)-benzoylamino]-2-benzenesulfonylamino-propionic acid 
• 168892-66-8 4-(2-((tert-butoxycarbonyl)amino)ethoxy)benzoic acid 

Relevant articles and documents

Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury

Acute kidney injury (AKI) is associated with high morbidity and mortality. Cisplatin is a common chemotherapeutic, but its nephrotoxicity-driven AKI limits its clinical application. Currently, there are no specific and satisfactory therapies in the clinic for AKI. Inhibitors of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2) or histone deacetylase (HDACs) had shown renoprotective effects against AKI in preclinical studies. This study aimed to develop a novel therapeutic to prevent AKI progression by targeting PHD2 and HDACs simultaneously. We designed and synthesized a series of PHD2/HDACs hybrid inhibitors. The initial drug activity screening identified a candidate compound 31c, which exhibited potent inhibitory activities against PHD2 and HDAC1/2/6. Cellular analyses further showed that 31c did not affect cisplatin's antitumor activity in cancer cells but strongly protected cisplatin-induced toxicity on HK-2 cells. In vivo studies with the cisplatin-induced AKI mouse model demonstrated that 31c remarkably alleviated kidney dysfunction with suppressed plasma BUN/SCr and increased EPO levels. The potent renoprotective effects of 31c on AKI were confirmed by significant improvements in pathological kidney conditions in the mouse model. These results suggest that the novel PHD2/HDACs hybrid inhibitor, 31c, has a clinical potential as the renoprotective agent for the treatment/prevention of cisplatin-induced AKI for various cancers.

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2AReceptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents

Adenosine is an immunosuppressive factor in the tumor microenvironment mainly through activation of the A2A adenosine receptor (A2AR), which is a mechanism hijacked by tumors to escape immune surveillance. Small-molecule A2AR antagonists are being evaluat

Dual inhibitor for prolyl hydroxylase and histone deacetylase, preparation method and application thereof

The invention discloses a new dual inhibitor for prolyl hydroxylase and histone deacetylase shown as formula I, a preparation method and an application thereof. The new dual inhibitor is capable of selectively promoting the level of hypoxia-inducible fact